Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy

Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy

Audrey M Sigmund,* Kieran D Sahasrabudhe,* Bhavana Bhatnagar Division of Hematology, Department of Internal Medicine, The Ohio State University and the Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA*These authors contributed equally to this workCorrespondence: Bhavana Bha...

Full description

Bibliographic Details
Main Authors: Sigmund AM, Sahasrabudhe KD, Bhatnagar B
Format: Article
Language:English
Published: Dove Medical Press 2020-11-01
Series:Blood and Lymphatic Cancer : Targets and Therapy
Subjects:
blinatumomab
bite antibody
b-cell acute lymphoblastic leukemia
relapsed and refractory disease
measurable residual disease
mrd
Online Access:https://www.dovepress.com/evaluating-blinatumomab-for-the-treatment-of-relapsedrefractory-all-de-peer-reviewed-article-BLCTT

Internet

https://www.dovepress.com/evaluating-blinatumomab-for-the-treatment-of-relapsedrefractory-all-de-peer-reviewed-article-BLCTT

Similar Items